Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bushman

Showing results (1081-1090 of 1,102) with videos related to

Pageof 111
Sort By:
Nature Medicine|January 29, 2020
Lentiviral gene therapy for X-linked chronic granulomatous diseaseDonald B Kohn, Claire Booth, Elizabeth M Kang, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2021
SARS-CoV-2 variants associated with vaccine breakthrough in the Delaware Valley through summer 2021Andrew D Marques, Scott Sherrill-Mix, John Everett, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Mbio|February 8, 2022
SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021Andrew D Marques, Scott Sherrill-Mix, John K Everett, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2021
Epidemiologic Characteristics Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen-Based Test Results, Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Cycle Threshold Values, Subgenomic RNA, and Viral Culture Results From University TestingLaura Ford, Christine Lee, Ian W Pray, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Blood|January 27, 2026
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory DiarrheaViktoria Blumenberg, Filippo Birocchi, Angela Shih, et al.
Pageof 111

Showing results (1081-1090 of 1,102) with videos related to

Sort By:
Pageof 111
Nature Medicine|January 29, 2020
Lentiviral gene therapy for X-linked chronic granulomatous diseaseDonald B Kohn, Claire Booth, Elizabeth M Kang, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2021
SARS-CoV-2 variants associated with vaccine breakthrough in the Delaware Valley through summer 2021Andrew D Marques, Scott Sherrill-Mix, John Everett, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.
Mbio|February 8, 2022
SARS-CoV-2 Variants Associated with Vaccine Breakthrough in the Delaware Valley through Summer 2021Andrew D Marques, Scott Sherrill-Mix, John K Everett, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2021
Epidemiologic Characteristics Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen-Based Test Results, Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Cycle Threshold Values, Subgenomic RNA, and Viral Culture Results From University TestingLaura Ford, Christine Lee, Ian W Pray, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Nature Medicine|March 22, 2022
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Julie S Barber-Rotenberg, In-Young Jung, et al.
Blood|January 27, 2026
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory DiarrheaViktoria Blumenberg, Filippo Birocchi, Angela Shih, et al.
Pageof 111